−1.50TWD
−639.89 MTWD
1.79 BTWD
353.79 M
About ADIMMUNE CORPORATION
Sector
CEO
Chung Cheng Liu
Headquarters
Taichung
Website
Founded
1965
ISIN
TW0004142005
FIGI
BBG001636XY8
Adimmune Corp. engages in the manufacturing and sales of influenza vaccine. Its products include Trivalent Influenza vaccine, Tetravalent Influenza vaccine, Influenza A (H1N1) Virus Monovalent Vaccine, Japanese Encephalitis Vaccine (JEV), and Tetanus toxoid, and purified Tuberculin. Its business scope includes research and development, processing, manufacturing, and trading of serum, vaccines, test reagents, biological agents and their bacterial liquids, and raw materials. The company was founded on December 22, 1965 and is headquartered in Taichung, Taiwan.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 4142 is 27.35 TWD — it has decreased by 4.04% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on TWSE exchange ADIMMUNE CORPORATION stocks are traded under the ticker 4142.
ADIMMUNE CORPORATION is going to release the next earnings report on May 7, 2024. Keep track of upcoming events with our Earnings Calendar.
4142 stock is 6.34% volatile and has beta coefficient of 0.19. Check out the list of the most volatile stocks — is ADIMMUNE CORPORATION there?
One year price forecast for ADIMMUNE CORPORATION has a max estimate of 35.00 TWD and a min estimate of 35.00 TWD.
4142 earnings for the last quarter are 0.98 TWD per share, whereas the estimation was 1.11 TWD resulting in a −11.71% surprise. The estimated earnings for the next quarter are −0.72 TWD per share. See more details about ADIMMUNE CORPORATION earnings.
ADIMMUNE CORPORATION revenue for the last quarter amounts to 1.09 B TWD despite the estimated figure of 1.09 B TWD. In the next quarter revenue is expected to reach 108.00 M TWD.
Yes, you can track ADIMMUNE CORPORATION financials in yearly and quarterly reports right on TradingView.
4142 stock has risen by 3.01% compared to the previous week, the month change is a 2.63% rise, over the last year ADIMMUNE CORPORATION has showed a 32.47% decrease.
4142 net income for the last quarter is −413.88 M TWD, while the quarter before that showed 263.71 M TWD of net income which accounts for −256.95% change. Track more ADIMMUNE CORPORATION financial stats to get the full picture.
Today ADIMMUNE CORPORATION has the market capitalization of 12.24 B, it has decreased by 1.13% over the last week.
Like other stocks, 4142 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ADIMMUNE CORPORATION stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ADIMMUNE CORPORATION technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ADIMMUNE CORPORATION stock shows the sell signal. See more of ADIMMUNE CORPORATION technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on ADIMMUNE CORPORATION future price: according to them, 4142 price has a max estimate of 35.00 TWD and a min estimate of 35.00 TWD. Read a more detailed ADIMMUNE CORPORATION forecast: see what analysts think of ADIMMUNE CORPORATION and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ADIMMUNE CORPORATION EBITDA is −498.62 M TWD, and current EBITDA margin is −27.93%. See more stats in ADIMMUNE CORPORATION financial statements.